CII
AMAG

CR Intrinsic Investors’s AMAG Pharmaceuticals AMAG Stock Holding History

CR Intrinsic Investors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-107,282
Closed -$2.39M – 423
2013
Q2 		$2.39M Buy
+107,282
New +$2.36M 0.08% 257

Other funds holding AMAG

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CR Intrinsic Investors's AMAG Position: Q3 2013 in Review

CR Intrinsic Investors sold out of AMAG Pharmaceuticals (AMAG) in Q3 2013, closing a stake of 107,282 shares — an estimated $2.39M sold.

CR Intrinsic Investors first reported a position in AMAG in Q2 2013 and held it in 1 quarter. The position peaked at $2.39M in Q2 2013. 97 funds tracked by Wall St. Rank hold AMAG as of Q3 2013.

  • CR Intrinsic Investors reported no remaining AMAG Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 107,282 AMAG Pharmaceuticals shares in Q3 2013, an estimated $2.39M.
  • CR Intrinsic Investors first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's AMAG Pharmaceuticals position peaked at $2.39M in Q2 2013.
  • 97 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2013.

Based on CR Intrinsic Investors's 13F filing for Q3 2013, filed 14 Nov 2013.